$CNTN

Tharimmune, Inc.

CIK:0001861657|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenue
Total revenue	$ 1,495,859		$ 1,495,859
Operating expenses
Research and development		123,638		215,087
General and administrative	2,698,013	1,304,956	37,919,194	3,257,555
Total operating expenses	2,698,013	1,428,594	37,919,194	3,472,642
Loss from operations	(1,202,154)	(1,428,594)	(36,423,335)	(3,472,642)
Other income (expense)
Interest expense		(6,161)		(14,632)
Interest income	311,848	2,168	630,026	15,604
Unrealized loss from digital assets holdings	(23,735,950)		(38,749,254)
Total other income (expense), net	(23,424,102)	(3,993)	(38,119,228)	972
Total loss before income taxes	(24,626,256)	(1,432,587)	(74,542,563)	(3,471,670)
Provision (benefit) for income taxes	(6,672,175)		(10,892,415)
Net loss from continuing operations	(17,954,081)	(1,432,587)	(63,650,148)	(3,471,670)
Net loss from discontinued operations	(1,300,745)	(422,566)	(2,947,875)	(925,187)
Net loss	$ (19,254,826)	$ (1,855,153)	$ (66,598,023)	$ (4,396,857)
Net loss per share:
Continuing operations - basic	$ (0.08)	$ (0.50)	$ (0.30)	$ (1.27)
Continuing operations - diluted	(0.08)	(0.50)	(0.30)	(1.27)
Discontinued operations - basic	(0.01)	(0.15)	(0.01)	(0.34)
Discontinued operations - diluted	$ (0.01)	$ (0.15)	$ (0.01)	$ (0.34)
Weighted average number of common shares outstanding:
Basic	216,864,938	2,877,327	212,310,722	2,725,863
Diluted	216,864,938	2,877,327	212,310,722	2,725,863
Network Validation Revenue [Member]
Revenue
Total revenue	$ 191,226		$ 191,226
Other Revenue [Member]
Revenue
Total revenue	$ 1,304,633		$ 1,304,633

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (66,598,023)	$ (4,396,857)
Net loss from discontinued operations	(2,947,875)	(925,187)
Net loss from continuing operations	(63,650,148)	(3,471,670)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash revenue from network validation and services	(1,515,630)
Unrealized loss from digital assets holdings and receivables	38,749,254
Deferred tax benefit	(10,892,415)
Stock based compensation	32,329,614	430,917
Increase in operating assets:
Prepaid expenses and other current assets	(764,031)	(150,755)
Increase (decrease) in operating liabilities:
Accounts payable	(158,596)	329,453
Accrued expenses	477,255	(225,964)
Net cash used in operating activities – continuing operations	(5,424,697)	(3,088,019)
Net cash used in operating activities – discontinued operations	(4,448,795)	(743,512)
Net cash used in operating activities	(9,873,492)	(3,831,531)
Cash flows from investing activities:
Purchase of digital assets	(59,586,023)
Collateral paid on digital asset option contracts	(1,000,000)
Net cash used in investing activities	(60,586,023)
Cash flows from financing activities:
Proceeds from issuance of common stock upon registered direct public equity offerings	54,894,300
Proceeds from issuance of common stock upon private investment in public equity offerings		2,500,000
Proceeds from issuance of common stock upon at-the-market offerings	39,791,684	266,625
Proceeds from exercise of common stock warrants	186,579
Payment of deferred offering costs and other issuance costs	(3,627,422)	(272,246)
Proceeds from insurance premium financing liability		285,178
Repayment of insurance premium financing liability		(200,638)
Repayments of note payable		(64,769)
Net cash provided by financing activities	91,245,141	2,514,150
Net increase (decrease) in cash	20,785,626	(1,317,381)
Cash, beginning of period – including discontinued operations	17,032,748	3,559,361
Cash, end of period – including discontinued operations	37,818,374	2,241,980
Cash, end of period – discontinued operations	576,806
Cash, end of period –continuing operations	37,241,568	2,241,980
Supplemental disclosure of non-cash activities:
Digital assets acquired but not yet settled in cash	77,083
Supplemental disclosure of non-cash financing activities:
Amortization of deferred offering cost from ATM offering		24,832
Reduction of premium related to insurance premium financing		101,102
Issuance of note payable for settlement of previously incurred professional fees		314,485
Issuance of options to settle liability		$ 200,212

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets
Cash and cash equivalents	$ 37,241,568	$ 12,007,148
Prepaid expenses and other current assets	3,274,069	197,383
Current assets held for sale	700,997	5,181,535
Total current assets	41,216,634	17,386,066
Digital assets	523,353,752	501,760,369
Total assets	564,570,386	519,146,435
Current liabilities
Accounts payable	916,244	521,201
Accrued expenses	983,715	506,460
Current liabilities held for sale	726,039	2,258,703
Total current liabilities	2,625,998	3,286,364
Deferred tax liability	107,041,776	117,934,191
Total liabilities	109,667,774	121,220,555
Commitments and contingencies (see Note 7)
Stockholders’ equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.0001 par value, 1,000,000,000 shares authorized as of June 30, 2026 and December 31 2025, 77,273,206 shares and 37,112,466 shares issued and 77,272,960 shares and 37,112,220 shares outstanding as of June 30, 2026 and December 31 2025, respectively	7,727	3,711
Additional paid-in capital	594,380,217	470,809,478
Accumulated deficit	(139,415,367)	(72,817,344)
Treasury stock, at cost, 246 shares held in treasury as of June 30, 2026 and December 31, 2025	(69,965)	(69,965)
Total stockholders’ equity	454,902,612	397,925,880
Total liabilities and stockholders’ equity	$ 564,570,386	$ 519,146,435